
## Sarah E Dilley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8605424/publications.pdf Version: 2024-02-01



**SADAH F DILLEV** 

#	Article	IF	CITATIONS
1	lt's time to re-evaluate cervical Cancer screening after age 65. Gynecologic Oncology, 2021, 162, 200-202.	1.4	14
2	Prehabilitation for medically frail patients undergoing surgery for epithelial ovarian cancer: a cost-effectiveness analysis. Journal of Gynecologic Oncology, 2021, 32, e92.	2.2	18
3	Human papillomavirus vaccination: Ongoing challenges and future directions. Gynecologic Oncology, 2020, 156, 498-502.	1.4	34
4	Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis. Gynecologic Oncology, 2019, 153, 381-384.	1.4	28
5	Regional Disparities in Ovarian Cancer in the United States. Cancer Health Disparities, 2019, 3, e1-e12.	0.5	0
6	Lessons Learned From Domestic and International Human Papillomavirus Vaccination Programs: A Review. Obstetrical and Gynecological Survey, 2018, 73, 94-95.	0.4	1
7	Do differences in medical comorbidities and treatment impact racial disparities in epithelial ovarian cancer?. Gynecologic Oncology, 2018, 149, 49-52.	1.4	11
8	Lessons learned from domestic and international human papillomavirus vaccination programs: a review. American Journal of Obstetrics and Gynecology, 2018, 218, 467-473.	1.3	11
9	HPV vaccination. Gynecologic Oncology, 2018, 148, 3-4.	1.4	6
10	The Impact of Racial, Geographic, and Socioeconomic Risk Factors on the Development of Advanced-Stage Cervical Cancer. Journal of Lower Genital Tract Disease, 2018, 22, 269-273.	1.9	10
11	The challenge of HPV vaccination uptake and opportunities for solutions: Lessons learned from Alabama. Preventive Medicine, 2018, 113, 124-131.	3.4	58
12	Catch-up human papillomavirus vaccination: don't throw the baby out with the bathwater. The Lancet Child and Adolescent Health, 2018, 2, 690-691.	5.6	0
13	Treatment of low-grade endometrial stromal sarcoma in a nulligravid woman. Gynecologic Oncology, 2018, 151, 6-9.	1.4	0
14	Preventing human papillomavirus–related cancers:ÂweÂareÂallÂin this together. American Journal of Obstetrics and Gynecology, 2017, 216, 576.e1-576.e5.	1.3	7
15	Racial, Geographic and Socioeconomic Risk Factors for Development of Advanced Stage Cervical Cancer [15]]. Obstetrics and Gynecology, 2017, 129, 106S-106S.	2.4	0
16	Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention. Gynecologic Oncology, 2017, 146, 373-379.	1.4	45
17	Malignant Brenner tumor associated with a germline BRCA2 mutation. Gynecologic Oncology Reports, 2017, 21, 17-19.	0.6	3
18	The Evolution of and Evidence for Opportunistic Salpingectomy. Obstetrics and Gynecology, 2017, 130, 814-824	2.4	35

SARAH E DILLEY

#	Article	IF	CITATIONS
19	The impact of physician burnout on clinical and academic productivity of gynecologic oncologists: A decision analysis. Gynecologic Oncology, 2017, 146, 642-646.	1.4	31
20	Recent trends in racial and regional disparities in cervical cancer incidence and mortality in United States. PLoS ONE, 2017, 12, e0172548.	2.5	117
21	Distance from a Comprehensive Cancer Center: A proxy for poor cervical cancer outcomes?. Gynecologic Oncology, 2016, 143, 617-621.	1.4	38
22	Two cases of endocervical villoglandular adenocarcinoma: Support for conservative management. Gynecologic Oncology Reports, 2015, 12, 34-36.	0.6	3
23	Socioeconomic status as a predictor of adherence to treatment guidelines for early-stage ovarian cancer. Gynecologic Oncology, 2015, 138, 121-127.	1.4	49
24	124: Buprenorphine vs methadone for maintenance of opioid addiction during pregnancy: a cost-effectiveness analysis. American Journal of Obstetrics and Gynecology, 2013, 208, S65-S66.	1.3	2